1714088-51-3

Telisotuzumab vedotin (Teliso-V) is an antibody drug conjugate that targets the MET receptor.

In the first in-human phase I trial for Teliso-V, NSCLC patients with MET-overexpressing tumors received monotherapy. The results of this innovative trial indicated favorable safety and tolerability responses and also showed promising antitumor activity in NSCLC patients with MET overexpression.